News

This recent designation marks the seventh issued patent to cover Indiplon. It will provide Neurocrine with patent exclusivity for Indiplon Polymorph Form III, a novel form of the

In the US an orphan drug designation may be granted to drugs that treat rare life-threatening diseases that affect less than 200,000 US persons. Such designation provides a

Glaucoma is characterized by increased fluid pressure within the eye, or intraocular pressure, which often causes the degeneration of the optic nerve and blindness. Glaucoma is the second

Not only did the new once daily formulation of Sanctura improve all the symptoms and signs of overactive bladder, it was also was very well tolerated among the

Barr’s application to market an abbreviated form of the drug has already been accepted for filling by the FDA, triggering the response by J&J. The suit has been

The decision by the FDA to approve new prescribing information for Angiomax (bivalirudin) is effective immediately. The label will now include patients undergoing percutaneous coronary intervention (PCI) in

The phase I trial conducted in early 2005 was designed to evaluate AL-108’s safety, tolerability and pharmacokinetics in healthy subjects. The study was double-blind by design and participants

The phase I clinical trial of RiVax represents the first ricin toxin vaccine ever to be clinically tested in humans. In the dose-escalating, open-label trial, three cohorts of

The multi-center study will be conducted in more than 50 US sites recruiting around 400 patients. One-half of the postherpetic neuralgia (PHN) patients will be assigned to receive